Editorial
Bone marrow transplantation in the treatment of autoimmune diseases: evolving concepts and early experience Autoimmune diseases (AD) present a wide spectrum of clinical problems both in type and severity. In the absence of definitive treatment, management is aimed at reducing immunologically induced inflammation and therefore symptoms and damage to vital organs. Unfortunately this often involves the use of potentially toxic substances either acutely (e.g. cyclophosphamide induced aplastic anaemia) or, perhaps more insidiously and importantly, cumulatively (e.g. steroid induced osteoporosis). A delicate benefit/risk ratio exists.' 1 Recent improvements in the techniques of bone marrow transplantation (BMT) have allowed this to become a realistic option in the treatment of severe AD. These mainly involve an increased use of peripherally collected (harvested) haematological stem cells (HSC), more refined and precise manipulation of the obtained transplant product ex vivo ('graft engineering'), and better support therapy throughout the aplastic period with growth factors and antimicrobials. Following autologous peripheral HSC BMT this aplastic period is around [10] [11] [12] days. In addition, the increasing use of autologous, as opposed to allogenic, BMT eliminates the risk of graft-versushost disease (GvHD) and carries a smaller mortality of around 3%.
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That BMT may replace adequate haemopoietic and immunological function long term is established following the seminal work from E. Donnel Thomas 25 years ago in Seattle.' Allogenic BMT was later extended to non-malignant conditions such as sickle cell disease and thalassemia and autologous BMT employed increasingly in haematological (e.g. lymphoma), solid tumour (e.g. breast) and now AD.
Just as with the early pioneering work from Seattle, the AD program has a basis in animal model studies including the somewhat surprising observation that autologous BMT may cure experimental AD in animals genetically predisposed to AD.8 In addition the concept is strengthened by the observation over some years that patients undergoing BMT for conventional reasons who coincidentally suffered from an AD, often experienced improvement or remission of the AD as well.9-12. This data is often confusing as the severity, activity and manifestations of the AD are not always completely recorded and the patients received many different conditioning regimens. There are also some dramatic failures recorded 13 and clearly the situation remains open.
The term 'stem cell therapy' in the context of AD treatment is somewhat misleading because there is no evidence yet that the HSC do more than reconstitute the ablated immune and haemopoietic system; in other words a rescue or support function. This is exactly the same as the original use of HSC for treatment of aplastic anaemia or other situations when the bone marrow has been ablated, e.g. leukaemia. Obviously in some situations, e.g. aplastic anaemia or genetic disorders such as sickle cell disease allogenic HSCs are necessary.
In the context of AD treatment, besides the obvious more profound (and with HSC support, hopefully safer) immunosuppression, there is the hope (and, from animal work, the expectation) that during the reconstitution of the immune system, tolerance could occur to previously autoaggressive antigens. The concordance rate between homozygous twins for AD (rheumatoid arthritis 18%; multiple sclerosis 40% systemic lupus erythematosus 15%)'4 indicates that the genetic component is alone insufficient for full disease expression. This was the reason to begin with the safer (3% mortality) autologous programme rather than allogenic (15-35% mortality).
Recent years have seen rapid advances in the techniques of mobilizing stem and progenitor cells from the bone marrow using G-CSF and cyclophosphamide to allow peripheral collection. Apart from the obvious convenience of this, it seems that peripheral HSC reconstitute the haematopoietic and immune systems faster than marrow HSC. A potential disadvantage is that peripherally obtained HSC contain more mature T and B cells than bone marrow derived HSCs and require more purging of unwanted cells. Purging implies either the positive selection of desired cells, e.g. CD34 stem and early progenitors or the removal of unwanted cells using monoclonal antibody based columns or complement fixing antibodies. A minimum of 2 x 106 CD34 cells/kg recipient body weight are required for haematological and immune reconstitution and < 1 x 105 is considered to be T cell depleted.
It is not clear whether T and B cells must be purged from the graft in treating ADs, although it would seem logical. In the treatment of leukaemia, the removal of T cells reduces GvHD but also the desired graftversus-leukaemia reaction resulting in more relapses. For AD it is simply not known, though most groups have performed some form of T cell reduction. There is some early data for' and against.&dquo; More data and comparative studies are required to answer these critical questions.
In order to coordinate these new therapies a combined effort from the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow transplantation (EBMT) has begun with a centralized data base and a consensus statement resulting from an international meeting in Basel, Switzerland, September 1996.&dquo;
Early results on around 35 patients treated only for AD are available, more than half of whom had multiple sclerosis (MS). Most have shown a tendency toward stabilization or improvement. In the patients with rheumatic ADs, the majority have had systemic sclerosis or CREST syndrome, with some encouraging early results, both with respect to skin changes and pulmonary hypertension.'g>19 All authors stress the early nature (maximum 18 months) follow-up these cases and need for comparative studies. Toxicity has been not more than predicted from previous BMT experience and no group has reported failure to obtain enough CD34 cells for reconstitution.
Many questions remain, especially that of allogenic versus autologous BMT. Perhaps 'cure' will only be possible with a new bone marrow, though there is some data against this.l3 Certainly the clinical features of GvHD seen in allogenic BMT are similar to many ADs such as systemic sclerosis and Sj6gren's syndrome, and would be difficult to distinguish from the original condition being treated.2° The reconstitution of the immune system following BMT has many parallels with normal ontogeny, and therefore carries the realistic hope of peripheral tolerization. Also not clear is the degree of immune ablation required, especially total body irradiation (TBI). This carries a greater risk of late tumour but may give a higher chance of eliminating memory cells. The degree (if any) of graft T cell purging has to be established. It is likely that different ADs will require different approaches and if the basic protocols are followed as recommended in the EULAR/EBMT consensus statement, the rational comparative trials will be able to be designed. An integral part of this is the patient selection and the close collaboration of colleagues in the rheumatology/immunology and BMT disciplines.
